Eudragit® microparticles as a possible tool for ophthalmic administration of acyclovir

Journal of Microencapsulation

Volumn 24, Issue 5, 2007, Pages 445-456

  Cortesi, Rita ^a   Ajanji, Sara C Lahm ^a   Sivieri, Elisa ^a   Manservigi, Marco ^a   Fundueanu, Gheorghe ^b   Menegatti, Enea ^a   Esposito, Elisabetta ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b PETRU PONI INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Romania)

Author keywords

Acyclovir; Eudragit ; Herpes simplex virus; Ocular delivery

Indexed keywords

ACICLOVIR; EUDRAGIT; EUDRAGIT RS; MICROSPHERE; ANTIVIRUS AGENT; DRUG CARRIER; EYE DROPS; METHYLMETHACRYLATE METHACRYLIC ACID COPOLYMER; METHYLMETHACRYLATE-METHACRYLIC ACID COPOLYMER; POLYMER; POLYMETHACRYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIALYSIS; DRUG DELIVERY SYSTEM; DRUG RELEASE; ELECTRON MICROSCOPY; ENCAPSULATION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; NONHUMAN; SPRAY DRYING; ANIMAL; CERCOPITHECUS; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; GROWTH, DEVELOPMENT AND AGING; METHODOLOGY; SCANNING ELECTRON MICROSCOPY; VERO CELL; VIRUS REPLICATION;

ACYCLOVIR; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; HERPESVIRUS 1, HUMAN; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; OPHTHALMIC SOLUTIONS; POLYMERS; POLYMETHACRYLIC ACIDS; VERO CELLS; VIRUS REPLICATION;

EID: 34347260313     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/02652040701374889     Document Type: Article

References (38)

1. Al-kassas, R. (2004) Design and in vitro evaluation of gentamicin-Eudragit® microspheres intended for intra-ocular administration. Journal of Microencapsulation, 21, pp. 71-81.
2. Blum, MR, Liao, SHT and Miranad, PD (1982) Overview of acyclovir pharmacokinetic disposition in adults and children. American Journal of Medicine, 73, pp. 186-192.
3. Broadhead, J., Rouan, SKE and Rhodes, CT (1993) The spray-drying of pharmaceuticals. Drug Development and Industrial Pharmacy, 18, pp. 1169-1206.
4. Bucolo, C., Maltese, A., Puglisi, G. and Pignatello, R. (2002) Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit® RS100 nanoparticle suspension. Ophthalmic Research, 34, pp. 319-323.
5. Calvo, P., Vila-Jato, JL and Alonso, MJ (1997) Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. International Journal of Pharmaceutics, 153, pp. 41-50.
6. Clarke, N., O'Connor, K. and Ramtoola, Z. (1998) Infuence of formulation variables on the morphology of biodegradable microparticles prepared by spray-drying. Drug Development and Industrial Pharmacy, 24, pp. 169-174.
7. Desai, SD and Blanchard, J. (2000) Pluronic F127-based ocular delivery system containing biodegradable polyisobutylcyanoacrylate nanocapsules of pilocarpine. Drug Delivery, 7, pp. 201-207.
8. Douglas, JM, Davis, LG, Remington, ML, Paulsen, CA, Perrin, EB, Goodman, P., Conner, JD, Ding, D. and Corey, L. (1988) A double-blind, placebo-controlled trial of the effect of chronically administered acyclovir on sperm production in men with frequently recurring genital herpes. Journal of Infection Diseases, 157, pp. 588-589.
9. Edwards, CA (1993) Anatomical and physiological basis: Physiological factors influencing drug absorption. Colonic drug absorption and metabolism, pp. 1-28. Marcel Dekker, New York
10. Esposito, E., Roncarati, R., Cortesi, R., Cervellati, F. and Nastruzzi, C. (2000) Production of Eudragit® microparticles by spray drying technique: Influence of experimental parameters on morphological and dimensional characteristics. Pharmaceutical Development Technology, 5, pp. 267-278.
11. Esposito, E., Menegatti, E. and Cortesi, R. (2005) Hyaluronan based microspheres as tools for drug delivery: A comparative study. International Journal of Pharmaceutics, 288, pp. 35-49.
12. Fruman, PA, Clair, MH St and Spector, T. (1984) Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase. Journal of Biological Chemistry, 259, pp. 9575-9579.
13. De Jalon, E Ga, Blanco-Priieto, MJ, Ygartua, P. and Santoyo, S. (2003) Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture. European Journal of Pharmaceutics and Biopharmaceutics, 56, pp. 183-187.
14. Gibson, PR, Fixa, B., Pekarkova, B., Batovsky, M., Radford-Smith, G., Tibitanzl, J., Gabalec, L., Florin, TH and Greinwald, R. (2006) Comparison of the efficacy and safety of Eudragit®-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacological Therapy, 23, pp. 1017-1026.
15. Hardy, JG (1993) Scintigraphic techniques in studying colonic drug absorption. Colonic drug absorption and metabolism., pp. 77-87. Marcel Dekker, New York
16. Hill, EL, Ellis, MN and Nguyen-Dinh, P. (1991) Antiviral and antiparasitic susceptibility testing. American Society for Microbiology, editors. Manual of Clinical Microbiology, pp. 1184-1191. ASM press, Washington DC
17. Kotiyan, PN and Vavia, PR (2001) Eudragit®'s role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol. European Journal of Pharmaceutics and Biopharmaceutics, 52, pp. 173-180.
18. Lin, AY, Augsburger, Nouman, LL, Muhammad and Pope, D A. (2001) Study of crystallization of endogenous surfactant in Eudragit® NE30D-free films and its influence on drug-release properties of controlled-release diphenhydramine HCl pellets coated with Eudragit® NE30D, AAPS Pharmsci 3 (2) article 14
19. Lowman, AM and Peppas, NA (1999) Hydrogels. Encyclopedia of Controlled Drug Delivery., pp. 397-418. Wiley, New York
20. Merodio, M., Irache, JM, Valamesh, F. and Mirshahi, M. (2002) Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. Biomaterial, 23, pp. 1587-1594.
21. Modiano, P., Salloum, E., Gillet-Terver, MN, Barbaud, A., Georges, JC, Thouvenot, D., Schmutz, JL and Weber, M. (1995) Acyclovir-resistant chronic cutaneous herpes simplex in Wiskott-Aldrich syndrom. British Journal of Dermatology, 133, pp. 475-478.
22. Nastruzzi, C., Esposito, E., Cortesi, R., Gambari, R. and Menegatti, E. (1993) Kinetics of bromocriptine release from microsphere: Comparative analysis between different in vitro models. Journal of Microencapsulation, 11, pp. 565-574.
23. Parris, DS and Harrington, JE (1982) Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates., 116, pp. 775-779.
24. Pope, LE, Marcelletti, JF, Katz, LR, Lin, JY, Katz, DH, Parish, ML and Spear, PG (1998) The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Research, 40, pp. 85-94.
25. Raffin, RP, Jornada, DS, Re, MI, Pohlmann, AR and Guterres, SS (2006) Sodium pantoprazole-loaded enteric microparticles prepared by spray drying: Effect of the scale of production and process validation. International Journal of Pharmaceutics, 324:1, pp. 10-18.
26. Rafiee-Tehram, M., Safaii-Nikui, N., Peteriet, H. and Beckert, T. (2001) Acrylic resins as rate-controlling membranes in novel formulation of a nine-day 17-beta-estradiol transdermal delivery system: In vitro and release modifier effect evaluation. Drug Development and Industrial Pharmacy, 27, pp. 431-437.
27. Reardon, JE and Sector, T. (1989) Herpes simplex virus type I DNA polymerase: Mechanism of inhibition by acyclovir triphosphate. Journal of Biological Chemistry, 264, pp. 7405-7411.
28. Reichman, RC, Badger, GJ, Mertz, GJ, Corey, L., Richman, DD, Connor, JD, Redfield, D., Savoia, MC, Oxman, MN and Bryson, Y. (1984) Treatment of recurrent genital herpes simplex infections with oral acyclovir: A controlled trial. Journal of the American Medical Association, 251, pp. 2103-2107.
29. Reid, R., Mar, EV, Huang, ES and Topal, MD (1988) Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviruses and human polymerises. Journal of Biological Chemistry, 263, pp. 3898-3904.
30. Richards, DM, Carmine, AA, Brogden, RN, Heel, RC, Speight, TM and Avery, GS (1983) Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy. Drugs, 26, pp. 378-438.
31. Sacchetti, M. and Van Oort, MM (1996) Spray-drying and supercritical fluid particle generation technique. Inhalation aerosol: Physical and biological basis for therapy., pp. 337-384. Marcel Dekker, New York
32. Stahlmann, R., Klug, S., Lewandowski, C., Chahoud, I., Bochert, G., Merker, HJ and Heubert, D. (1987) Teratogenicity of acyclovir in rats. Infection, 15, pp. 261-262.
33. Tucker, WE (1982) Pre-clinical toxicology profile of acyclovir: An overview. American Journal of Medicine, 73, pp. 27-30.
34. Van Sorge, AA, Wijnen, PH, Van Delft, JL, Coré-Bodelier, VMW Carballosa and Van Haeringen, NJ (1999) Flurbiprofen, S(+), eyedrops: Formulation, enantiomeric assay, shelflife and pharmacology. Pharmaceutical World Sciences, 21, pp. 91-95.
35. Verma, PR and Iyer, SS (2000) Transdermal delivery of propranolol using mixed grades of Eudragit®: Design and in vitro and in vivo evaluation. Drug Development and Industrial Pharmacy, 26, pp. 471-476.
36. Walro, DG and Rosenthal, KS (1997) The antiviral xanthate compound D609 inhibits herpes simplex virus type 1 replication and protein phosphorylation. Antiviral Research, 36, pp. 63-72.
37. Washington, C. (1990) Drug release from microdisperse systems: A critical review. International Journal of Pharmaceutics, 58, pp. 1-12.
38. Wolff, RK and Niven, RW (1994) Generation of aerosolized drugs. Journal of Aerosol Medicine, 7, pp. 89-106.